TABLE 1

Subject characteristics of type 2 diabetic patients participating in the study

ParameterNumberMean ± SDRange
Sex (female/male)3/9
Age (years)61 ± 1043–74
Duration of diabetes (years)7 ± 62–22
HbA1c (%)7.3 ± 1.56–11.4
BMI (kg/m2)30.0 ± 3.724–33
Blood pressure (mmHg)
 Systolic139 ± 10120–160
 Diastolic81 ± 572–90
Creatinine (mg/dL)0.9 ± 0.20.7–1.1
Cholesterol (mg/dL)
 Total205 ± 51135–297
 LDL123 ± 4634–222
 HDL46 ± 1030–55
Metformin (number, dose [mg/day])82,200 ± 3782,000–3,000
Glibenclamide (number, dose [mg/day])34.7 ± 2.03.5–7.0
Bedtime insulin (number, dose [IU/day])11616
Intensive insulin therapy (number, dose [IU/day])347.7 ± 40.016–103
Nephropathy1
Neuropathy3
Retinopathy0
Macroangiopathy2
Hypertension9
Fasting plasma glucose at screening (mmol/L)8.2 ± 1.76.5–11.0
Fasting plasma glucose after antidiabetic therapy discontinuation (mmol/L)10.1 ± 2.98.5–17.0